questions is April 19, 2021. Applications and other information regarding the CDFI Fund and its programs may be obtained from the CDFI Fund's website at *http://www.cdfifund.gov.* The CDFI Fund will post on its website responses to questions of general applicability regarding the CDFI Bond Guarantee Program.

B. The CDFI Fund's contact information is as follows:

TABLE 2—CONTACT INFORMATION

Type of question	Telephone number (not toll free)	Email addresses
CDFI Bond Guarantee Program	(202) 653–0421 Option 5	*bgp@cdfi.treas.gov.*
CDFI Certification	(202) 653–0423	*ccme@cdfi.treas.gov.*
Certification, Compliance Monitoring and Evaluation	(202) 653–0423	*ccme@cdfi.treas.gov.*
Information Technology Support	(202) 653–0422	*AMIS@cdfi.treas.gov.*

C. Communication with the CDFI Fund. The CDFI Fund will communicate with applicants, Qualified Issuers, Program Administrators, Servicers, Certified CDFIs and Eligible CDFIs, using the contact information maintained in their respective AMIS accounts. Therefore, each such entity must maintain accurate contact information (including contact person and authorized representative, email addresses, fax numbers, phone numbers, and office addresses) in its respective AMIS account. For more information about AMIS, please see the AMIS Landing Page at *https://amis.cdfifund.gov.*

VII. Information Sessions and Outreach

The CDFI Fund may conduct webcasts, webinars, or information sessions for organizations that are considering applying to, or are interested in learning about, the CDFI Bond Guarantee Program. The CDFI Fund intends to provide targeted outreach to both Qualified Issuer and Eligible CDFI participants to clarify the roles and requirements under the CDFI Bond Guarantee Program. For further information, or to sign up for alerts, please visit the CDFI Fund's website at *http://www.cdfifund.gov.*

Authority: Pub. L. 111–240; 12 U.S.C. 4701, *et seq.;* 12 CFR part 1808; 12 CFR part 1805;12 CFR part 1815.

Jodie L. Harris,

Director, Community Development Financial Institutions Fund.

[FR Doc. 2021–04429 Filed 3–3–21; 8:45 am]

BILLING CODE 4810–70–P

U.S.-CHINA ECONOMIC AND SECURITY REVIEW COMMISSION

Notice of Open Public Hearing

AGENCY: U.S.-China Economic and Security Review Commission.

ACTION: Notice of open public hearing.

SUMMARY: Notice is hereby given of the following hearing of the U.S.-China Economic and Security Review Commission. The Commission is mandated by Congress to investigate, assess, and report to Congress annually on ''the national security implications of the economic relationship between the United States and the People's Republic of China.'' Pursuant to this mandate, the Commission will hold a public hearing in Washington, DC, on March 19, 2021, on ''U.S. Investment in China's Capital Markets and Military-Industrial Complex.''

DATES: The hearing is scheduled for Friday, March 19, 2021, 9:15 a.m.

ADDRESSES: This hearing will be held with panelists and Commissioners participating in-person or online via videoconference. Members of the audience will be able to view a live webcast via the Commission's website at *www.uscc.gov.* Also, please check the Commission's website for possible changes to the hearing schedule. *Reservations are not required to attend the hearing.*

FOR FURTHER INFORMATION CONTACT: Any member of the public seeking further information concerning the hearing should contact Jameson Cunningham, 444 North Capitol Street NW, Suite 602, Washington DC 20001; telephone: 202–624–1496, or via email at *jcunningham@uscc.gov. Reservations are not required to attend the hearing.*

ADA Accessibility: For questions about the accessibility of the event or to request an accommodation, please contact Jameson Cunningham via email at *jcunningham@uscc.gov.* Requests for an accommodation should be made as soon as possible, and at least five business days prior to the event.

SUPPLEMENTARY INFORMATION:

Background: This is the third public hearing the Commission will hold during its 2021 report cycle. The hearing will examine the Chinese government's use of capital markets to advance its technology and defense capabilities and evaluate the risks of U.S. investors' capital being leveraged for such ends. The opening panel will examine the evolving role of the state in China's capital markets, including the Chinese Communist Party's involvement in corporate governance. The second panel will review China's financial opening and U.S. and foreign investor participation in China's capital markets. The third panel will assess U.S. national security risks posed by investment in Chinese companies. The fourth panel will evaluate U.S. legal authority and current restrictions on outbound investment to China's capital markets.

The hearing will be co-chaired by Commissioner Robert Borochoff and Commissioner Jeffrey Fiedler. Any interested party may file a written statement by March 19, 2021 by transmitting to the contact above. A portion of the hearing will include a question and answer period between the Commissioners and the witnesses.

Authority: Congress created the U.S.-China Economic and Security Review Commission in 2000 in the National Defense Authorization Act (Pub. L. 106–398), as amended by Division P of the Consolidated Appropriations Resolution, 2003 (Pub. L. 108–7), as amended by Public Law 109–108 (November 22, 2005), as amended by Public Law 113–291 (December 19, 2014).

Dated: March 1, 2021.

Daniel W. Peck,

Executive Director, U.S.-China Economic and Security Review Commission.

[FR Doc. 2021–04507 Filed 3–3–21; 8:45 am]

BILLING CODE 1137–00–P

DEPARTMENT OF VETERANS AFFAIRS

Tiered Pharmacy Copayments for Medications; Calendar Year 2021 Update

AGENCY: Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: This Department of Veterans Affairs (VA) Notice updates the information on Tier 1 medications.

FOR FURTHER INFORMATION CONTACT: Joseph Duran, Office of Community Care, Veterans Health Administration, Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420; *Joseph.Duran2@va.gov;* 303–370–1637. This is not a toll-free number.

SUPPLEMENTARY INFORMATION: Section 17.110 of title 38, CFR, governs copayments for medications that VA provides to veterans. Section 17.110 provides the methodologies for establishing the copayment amount for each 30-day or less supply of medication provided by VA on an outpatient basis (other than medication administered during treatment).

Tier 1 medication means a multi-source medication that has been identified using the process described in paragraph (b)(2) of this section. Not less than once per year, VA will identify a subset of multi-source medications as Tier 1 medications. Only medications that meet all of the criteria in 38 CFR 17.110(b)(2)(i), (ii), and (iii) will be eligible to be considered Tier 1 medications, and only those medications that meet all of the criteria in paragraph (b)(2)(i) of this section will be assessed using the criteria in paragraphs (b)(2)(ii) and (iii).

Based on the methodologies set forth in § 17.110, this notice updates the list of Tier 1 medications for Calendar Year 2021. The Tier 1 medication list is posted on VA's Community Care website at the following link: *https://www.va.gov/COMMUNITYCARE/revenue_ops/copays.asp* under the heading ''Tier 1 Copay Medication List.''

The following table is the Tier 1 Copay Medication List that is effective January 1, 2021 and will remain in effect until December 31, 2021.

Condition	VA product name
Arthritis and Pain	Aspirin Buffered Tablet.
	Aspirin Chewable Tablet.
	Aspirin Enteric Coated Tablet.
	Allopurinol Tablet.
	Celecoxib Capsule.
	Diclofenac Tablet.
	Ibuprofen Tablet.
	Meloxicam Tablet.
	Naproxen Tablet.
Blood Thinners and Platelet Inhibitors	Clopidogrel Bisulfate Tablet.
	Warfarin Sodium Tablet.
Bone Health	Alendronate Tablet.
Cholesterol	Atorvastatin Tablet.
	Ezetimibe Tablet.
	Pravastatin Tablet.
	Rosuvastatin Calcium Tablet.
	Simvastatin Tablet.
Dementia	Donepezil Tablet.
Diabetes	Glimepiride Tablet.
	Glipizide Tablet.
	Metformin Hydrochloride (HCL) Tablet.
	Metformin HCL 24-Hour Sustained Action (SA) Tablet.
	Pioglitazone HCL Tablet.
Electrolyte Supplement	Potassium SA Tablet.
	Potassium SA dispersible Tablet.
Gastrointestinal Health	Famotidine Tablet.
	Omeprazole Enteric Coated (EC) Capsule.
	Pantoprazole Sodium EC Capsule.
Glaucoma and Eye Care	Diclofenac Solution.
	Dorzolamide 2%/Timolol 0.5% Solution.
	Latanoprost 0.005% Solution.
	Polyethylene Glycol 400/Polyethylene Glycol 4000 Solution.
	Carboxymethylcellulose Sodium Solution.
Heart Health and Blood Pressure	Amlodipine Tablet.
	Amiodarone HCL Tablet.
	Aspirin (see Arthritis and Pain).
	Atenolol Tablet.
	Carvedilol Tablet.
	ChlorthalidoneTablet.
	Clonidine Tablet.
	Diltiazem 24-Hour Capsule.
	Diltiazem HCL Tablet.
	Enalapril Maleate Tablet.
	Furosemide Tablet.
	Hydralazine HCL Tablet.
	Hydrochlorothiazide Tablet/Capsule.
	Hydrochlorothiazide/Lisinopril Tablet.
	Hydrochlorothiazide/Losartan Tablet.
	Hydrochlorothiazide/Triamterene Tablet/Capsule.
	Isosorbide Mononitrate SA Tablet.
	Lisinopril Tablet.
	Losartan Tablet.
	Metoprolol Succinate SA Tablet.
	Metoprolol Tartrate Tablet.
	Nifedipine SA Capsule.

Condition	VA product name
	Nitroglycerin sublingual Tablet.
	Prazosin HCL Capsule.
	Propranolol HCL Tablet.
	Spironolactone Tablet.
Mental Health	Amitriptyline HCL Tablet.
	Buspirone HCL Tablet.
	Bupropion HCL Tablet.
	Bupropion HCL SA (12HR–SR) Tablet.
	Bupropion HCL SA (24HR–XL) Tablet.
	Citalopram Hydrobromide Tablet.
	Duloxetine HCL EC Capsule.
	Escitalopram Oxalate Tablet.
	Fluoxetine Tablet/Capsule.
	Mirtazapine Tablet.
	Paroxetine Tablet.
	Sertraline HCL Tablet.
	Trazodone Tablet.
	Venlafaxine HCL Immediate (IR) Tablet.
	Venlafaxine HCL SA Capsule.
Respiratory Condition	Montelukast NA Tablet.
Seizures	Gabapentin Capsule.
	Lamotrigine Tablet.
	Topiramate Tablet.
Thyroid Conditions	Levothyroxine Sodium Tablet.
Urologic (Bladder and Prostate) Health	Alfuzosin HCL SA Tablet.
	Doxazosin Mesylate Tablet.
	Finasteride Tablet.
	Oxybutynin Chloride IR Tablet.
	Oxybutynin Chloride SA Tablet.
	Sildenafil Tablet.
	Tamsulosin HCL Capsule.
	Terazosin HCL Capsule.

Signing Authority

Denis McDonough, Secretary of Veterans Affairs, approved this document on February 26, 2021, and authorized the undersigned to sign and submit the document to the Office of the Federal Register for publication electronically as an official document of the Department of Veterans Affairs.

Luvenia Potts,

Regulation Development Coordinator, Office of Regulation Policy & Management, Office of the Secretary, Department of Veterans Affairs.

[FR Doc. 2021–04458 Filed 3–3–21; 8:45 am]

BILLING CODE 8320–01–P